Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
Joint Authors
Mazur, Włodzimierz
Simon, Krzysztof
Zarębska-Michaluk, Dorota
Buczyńska, Iwona
Tudrujek-Zdunek, Magdalena
Janczewska, Ewa
Dybowska, Dorota
Sitko, Marek
Dobracka, Beata
Jaroszewicz, Jerzy
Pabjan, Paweł
Klapaczyński, Jakub
Laurans, Łukasz
Socha, Łukasz
Tronina, Olga
Parczewski, Miłosz
Flisiak, Robert
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-03-03
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background and Aim.
The development of interferon- (IFN-) free regimens substantially improved efficacy of treatment for HCV, but despite excellent effectiveness the failures still occur.
The aim of our study was to evaluate the efficacy of retreatment with genotype specific direct acting antivirals- (DAA-) based regimens in nonresponders to previous IFN-free therapy.
Materials and Methods.
Analysed population consisted of 31 nonresponders to IFN-free regimen, which received second IFN-free rescue therapy, selected from 6228 patients included in a national database EpiTer-2.
Results.
Age and gender distribution were similar, whereas proportion of genotype 1b was slightly higher and genotype 4 lower in the whole population compared to studied one.
Patients included in the study demonstrated much more advanced fibrosis.
Primary therapy was discontinued in 12 patients, which were recognized as failures due to nonvirologic reason, whereas virologic reason of therapeutic failure was recognized in 19 patients which completed therapy.
Overall sustained virologic response (SVR) rate was 81% and 86% in intent-to-treat (ITT) and modified ITT analysis, respectively (74% and 78% in virologic failures, 92% and 100% in nonvirologic failures).
Resistance-associated substitutions (RAS) testing was carried out in 8 patients from the group of completed primary therapy and three of them had potential risk for failure of rescue therapy due to NS5A association, while two of them achieved SVR.
Conclusions.
We demonstrated moderate effectiveness of genotype specific rescue therapy in failures due to virologic reason and high in those who discontinued primary therapy.
Therefore rescue therapy with genotype specific regimens should be considered always if more potent regimens are not available.
American Psychological Association (APA)
Zarębska-Michaluk, Dorota& Buczyńska, Iwona& Simon, Krzysztof& Tudrujek-Zdunek, Magdalena& Janczewska, Ewa& Dybowska, Dorota…[et al.]. 2019. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology،Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1129837
Modern Language Association (MLA)
Zarębska-Michaluk, Dorota…[et al.]. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology No. 2019 (2019), pp.1-9.
https://search.emarefa.net/detail/BIM-1129837
American Medical Association (AMA)
Zarębska-Michaluk, Dorota& Buczyńska, Iwona& Simon, Krzysztof& Tudrujek-Zdunek, Magdalena& Janczewska, Ewa& Dybowska, Dorota…[et al.]. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Canadian Journal of Gastroenterology and Hepatology. 2019. Vol. 2019, no. 2019, pp.1-9.
https://search.emarefa.net/detail/BIM-1129837
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1129837